Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemplar vs. Calcijex in chronic kidney disease
NCT00062699Phase 4Terminated
- Sponsor
- Abbott Laboratories
- Start
- Apr 2003
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of paricalcitol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Time to Death. Started Apr 2003; status: terminated.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00062699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062699.